- Home
- FAMI vs GRI Comparison
FAMI vs GRI Comparison
Compare FAMI & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FAMI
- GRI
- Stock Information
- Founded
- FAMI 2015
- GRI 2018
- Country
- FAMI China
- GRI United States
- Employees
- FAMI N/A
- GRI N/A
- Industry
- FAMI Packaged Foods
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- FAMI Consumer Staples
- GRI Health Care
- Exchange
- FAMI Nasdaq
- GRI Nasdaq
- Market Cap
- FAMI 3.4M
- GRI 3.0M
- IPO Year
- FAMI 2018
- GRI N/A
- Fundamental
- Price
- FAMI $0.28
- GRI $0.69
- Analyst Decision
- FAMI
- GRI Strong Buy
- Analyst Count
- FAMI 0
- GRI 1
- Target Price
- FAMI N/A
- GRI $12.00
- AVG Volume (30 Days)
- FAMI 544.2K
- GRI 3.4M
- Earning Date
- FAMI 11-29-2024
- GRI 11-14-2024
- Dividend Yield
- FAMI N/A
- GRI N/A
- EPS Growth
- FAMI N/A
- GRI N/A
- EPS
- FAMI 0.13
- GRI N/A
- Revenue
- FAMI $86,261,500.00
- GRI N/A
- Revenue This Year
- FAMI N/A
- GRI N/A
- Revenue Next Year
- FAMI N/A
- GRI N/A
- P/E Ratio
- FAMI $2.28
- GRI N/A
- Revenue Growth
- FAMI N/A
- GRI N/A
- 52 Week Low
- FAMI $0.17
- GRI $0.30
- 52 Week High
- FAMI $2.35
- GRI $106.29
- Technical
- Relative Strength Index (RSI)
- FAMI 46.10
- GRI 46.42
- Support Level
- FAMI $0.28
- GRI $0.62
- Resistance Level
- FAMI $0.32
- GRI $1.00
- Average True Range (ATR)
- FAMI 0.03
- GRI 0.10
- MACD
- FAMI -0.00
- GRI -0.04
- Stochastic Oscillator
- FAMI 44.44
- GRI 16.42
About FAMI Farmmi Inc.
Farmmi Inc is a supplier of agricultural products. The products of the company are Shiitake Mushroom, Mu Er Mushroom and other edible fungi and other agricultural products. The majority of products are sold in mainland China.
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.